The Plasma-derived Factor VIII Market was valued at USD 12.7 Billion in 2022 and is projected to reach USD 21.4 Billion by 2030, growing at a CAGR of 6.8% from 2024 to 2030. The market growth is primarily driven by the increasing prevalence of hemophilia, a rare genetic bleeding disorder, along with the rising demand for advanced therapies. The shift towards plasma-derived therapies due to their enhanced safety profiles and efficacy has further fueled market expansion. The growing focus on improving healthcare infrastructure and the increasing availability of recombinant and plasma-derived treatments are also expected to contribute to market growth during the forecast period.
In addition, the rise in awareness about hemophilia and other bleeding disorders, along with advancements in plasma collection technologies, are anticipated to positively impact the market. North America dominated the global Plasma-derived Factor VIII Market in 2022, owing to the presence of a well-established healthcare system and increasing adoption of treatment therapies. However, the market is witnessing significant growth in emerging economies, where healthcare access is improving and healthcare expenditure is rising. The market is poised for substantial growth with innovations in Factor VIII therapies and strategic expansions in global markets.
Download Full PDF Sample Copy of Market Report @
Plasma-derived Factor VIII Market Research Sample Report
The Plasma-derived Factor VIII market is a critical segment within the global hemophilia treatment industry. Plasma-derived Factor VIII is primarily utilized in the treatment and management of hemophilia A, a bleeding disorder that affects both males and females, though it is more prevalent in males. The plasma-derived form is preferred over recombinant Factor VIII in some cases due to its close similarity to human plasma, which can result in fewer immune-related complications in patients. The application of plasma-derived Factor VIII has expanded significantly as awareness of hemophilia and other related bleeding disorders grows. Hospitals and pharmacies are the primary end-users of plasma-derived Factor VIII, with each segment contributing distinctively to the overall market. The demand for Factor VIII is driven by the increasing prevalence of hemophilia globally, aging populations, and advancements in medical technologies that improve the quality of life for individuals with bleeding disorders.
The market for plasma-derived Factor VIII by application has a significant presence in both hospitals and pharmacies, with hospitals being the larger contributor. Hospitals require large quantities of plasma-derived Factor VIII to treat patients in emergency settings and provide continuous care for individuals suffering from hemophilia. In these settings, Factor VIII is administered in various forms, including intravenous injections, to prevent or control bleeding episodes. On the other hand, pharmacies play a critical role in distributing plasma-derived Factor VIII for outpatient care and patient self-administration. The demand for Factor VIII in pharmacies is supported by the increasing number of individuals diagnosed with hemophilia who are receiving long-term treatments. Both segments contribute to a highly dynamic market that benefits from technological innovations, regulatory approvals, and the growing global healthcare infrastructure.
Hospitals are the largest consumers of plasma-derived Factor VIII, primarily due to the need for acute treatment in emergency situations. Hemophilia A patients often require urgent infusion of Factor VIII to manage spontaneous or trauma-induced bleeding episodes, making hospitals a critical market segment. In hospital settings, plasma-derived Factor VIII is typically administered intravenously under the supervision of medical professionals to ensure the correct dosage and monitor for any adverse reactions. Hospitals also tend to use larger quantities of plasma-derived Factor VIII compared to other segments, due to the complex needs of patients and the demand for rapid therapeutic intervention. Furthermore, hospitals frequently collaborate with pharmaceutical companies and blood banks to ensure a consistent supply of Factor VIII, which is necessary for both inpatient care and outpatient follow-ups.
The hospital segment benefits from continuous advancements in medical technologies, improved diagnosis methods, and a growing focus on patient care. As global healthcare standards improve, hospitals are increasingly adopting specialized treatment protocols for hemophilia that involve the use of plasma-derived Factor VIII. Additionally, government and private healthcare policies that focus on expanding access to essential medicines, including plasma-derived Factor VIII, have further supported the growth of this market. Hospitals are also investing in specialized care units for hemophilia patients, which is expected to drive long-term demand for plasma-derived Factor VIII in the hospital setting.
Pharmacies represent an important distribution channel for plasma-derived Factor VIII, particularly for patients who are undergoing long-term treatment for hemophilia A. With more patients managing their condition on an outpatient basis, the pharmacy segment plays a crucial role in ensuring that individuals have access to the necessary treatments. Patients who are stable and able to self-administer their infusions rely on pharmacies for the timely supply of Factor VIII. Pharmacies also facilitate the ease of access to Factor VIII in areas where hospital facilities may not be as easily reachable. The rising number of hemophilia patients opting for home treatment regimens has further contributed to the growing demand in the pharmacy segment. These trends are supported by improvements in patient education, ease of use of Factor VIII formulations, and the increasing availability of specialty pharmacies focused on blood disorders.
In addition to the growing patient base, pharmacies are benefitting from the increasing number of partnerships with pharmaceutical manufacturers, which help to ensure the availability of plasma-derived Factor VIII. Pharmacies are also adopting innovative technologies, such as patient support programs and home delivery services, which further drive market growth. As the pharmacy segment grows, the focus on personalized care and treatment customization becomes more pronounced, with pharmacies providing tailored recommendations and administration guidance. The broader access to plasma-derived Factor VIII through pharmacies is expected to continue to enhance treatment outcomes for hemophilia patients and expand market opportunities in both developed and emerging regions.
Several key trends are shaping the plasma-derived Factor VIII market. First, there is an increasing global prevalence of hemophilia, particularly in emerging markets, which is driving demand for Factor VIII treatments. As healthcare infrastructure improves and more individuals are diagnosed, the need for accessible treatment options grows. Furthermore, advancements in the biopharmaceutical industry, including the development of more efficient plasma collection and fractionation techniques, are expected to contribute to a more stable supply of Factor VIII. These innovations are also helping to reduce the cost of manufacturing, which could make plasma-derived Factor VIII more affordable and accessible, especially in low- and middle-income countries.
Another significant trend is the rising demand for home-based therapies. With improvements in Factor VIII formulation, including extended half-life products, more hemophilia patients are opting to self-administer their treatments at home. This shift is empowering patients to take control of their care and is creating growth opportunities for pharmacies as they cater to this segment. Additionally, healthcare policy changes aimed at increasing access to essential medicines, such as plasma-derived Factor VIII, particularly in underserved regions, are expected to further stimulate market growth. The development of new and improved versions of plasma-derived Factor VIII also presents significant opportunities for pharmaceutical companies, as they seek to differentiate their products in an increasingly competitive marketplace.
1. What is Plasma-derived Factor VIII used for?
Plasma-derived Factor VIII is primarily used to treat hemophilia A, a genetic disorder that causes bleeding due to a deficiency in clotting factor VIII.
2. How is Plasma-derived Factor VIII administered?
Plasma-derived Factor VIII is typically administered through intravenous injection to prevent or control bleeding episodes in hemophilia patients.
3. What is the difference between plasma-derived and recombinant Factor VIII?
Plasma-derived Factor VIII is derived from human blood plasma, while recombinant Factor VIII is produced using genetic engineering in laboratories.
4. Why do hospitals prefer Plasma-derived Factor VIII?
Hospitals prefer plasma-derived Factor VIII because of its effectiveness in treating bleeding episodes and the ability to closely mimic human plasma, reducing the risk of immune reactions.
5. What are the key applications of Plasma-derived Factor VIII?
The key applications include the treatment of hemophilia A, surgical bleeding prevention, and emergency management of bleeding episodes.
6. What factors are driving the growth of the Plasma-derived Factor VIII market?
The key factors include increasing hemophilia diagnosis rates, advancements in treatment options, and the growing adoption of home-based therapies.
7. What is the role of pharmacies in the Plasma-derived Factor VIII market?
Pharmacies play a critical role in distributing Factor VIII for outpatient care and home-based therapies, helping patients manage their condition on a long-term basis.
8. Are there any risks associated with Plasma-derived Factor VIII treatment?
The main risks include allergic reactions, viral transmission, and the potential for immune responses that could reduce the effectiveness of treatment.
9. How does the extended half-life of Plasma-derived Factor VIII impact treatment?
The extended half-life allows for less frequent infusions, improving convenience and quality of life for patients undergoing treatment.
10. What regions are seeing significant growth in the Plasma-derived Factor VIII market?
Significant growth is being seen in emerging markets such as Asia-Pacific, Latin America, and the Middle East, due to improving healthcare access and rising diagnosis rates.
For More Information or Query, Visit @ Plasma-derived Factor VIII Market Size And Forecast 2025-2030